A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India
eClinicalMedicine (2021) - Comments
pubmed: 34870133  doi: 10.1016/j.eclinm.2021.101218  issn: 2589-5370 

Prasad S Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, B S Garg, Nithya J Gogtay, Muralidhar Tambe, Sanjay Lalwani, Kiranjit Singh, Renuka Munshi, Sushant Meshram, T S Selvavinayagam, Krishna Pandey, Devi Madhavi Bhimarasetty, S R Ramakrishnan, Chetanraj Bhamare, Abhijeet Dharmadhikari, Rajeev Vadakkedath